IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP
Vulvar Cancer
National Cancer Institute (NCI)protein_peptidePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Vulvar Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Indocyanine Green Istanbul University | Phase 4 | BB |
TECHNETIUM-99 Institut de Cancérologie de Lorraine | Phase 3 | B |
Octreotide Pamoate Alliance for Clinical Trials in Oncology | Phase 3 | B |
e7 tcr-t cells Christian Hinrichs | Phase 2 | B |
Durvalumab M.D. Anderson Cancer Center | Phase 2 | B |
View all 34 →
Same molecule, other indications
IMMUNOTHERAPIC BIFUNCTIONAL FUSION PROTEIN COMPRISED OF A FULLY HUMAN IGG1 MONOCLONAL ANTIBODY (AVELUMAB) AGAINST HUMAN PROGRAMMED DEATH-LIGAND 1 (PD-L1) FUSED TO THE SOLUBLE EXTRACELLULAR DOMAIN OF TRANSFORMING GROWTH FACTOR-.BETA. (TGF-.BETA.) RECEPTOR II, WHICH ACTS AS A TGF-.BETA. TRAP is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →